TickerFacts.

Genelux Corp (GNLX): Capital Expenditures

Annual figures by period end, from SEC filings.

$1.10M
Year ended 2025-12-31
$3.41M
Trailing 12 months to 2026-06-30
+181.9%
3-year compound annual growth
2022-12-31: $49.0K2023-12-31: $1.02M2024-12-31: $381.0K2025-12-31: $1.10M$1.10M
2022-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$1.10M+188.2%2026-03-19, From 2025-01-01
2024-12-31$381.0K-62.8%2026-03-19, From 2024-01-01
2023-12-31$1.02Mn/m2025-03-28, From 2023-01-01
2022-12-31$49.0Kn/a2024-03-29, From 2022-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Genelux Corp (GNLX)2025-12-31$1.10M+188.2%
Alaunos Therapeutics, Inc. (TCRT)2025-12-31$98.0Kn/a
PRF Technologies Ltd. (PRFX)2025-12-31$2.0K-84.6%
Bioadaptives, Inc. (BDPT)2025-12-31$18.0Kn/a
Skinvisible, Inc. (SKVI)2025-12-31$4.1K-55.7%
Aditxt, Inc. (ADTX)2025-12-31$13.7Kn/a
Talphera, Inc. (TLPH)2024-12-31$0-100.0%
Lyell Immunopharma, Inc. (LYEL)2025-12-31$780.0K+68.1%
Neonc Technologies Holdings, Inc. (NTHI)2025-12-31$500.0Kn/a

Compare GNLX, TCRT, PRFX, BDPT side by side · Screen every company in Pharmaceutical Preparations ↗